Attendee search 

Guoqian Venture Capital is one of the two business platforms; the other is Guoqian Medical Technology Innovation Research Institute, which is an incubator/accelerator for startup and growth companies.
Guoqian Venture Capital is a professional and market-oriented venture capital firm that focuses on equity investment in early innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Focusing on innovative technologies and products. Due to currency restrictions, the firm can only invest in entities in China. The investment size is from ￥5 million （$750k) to ￥20 million ($ 3 million).
Guoqian Medical Technology Innovation Research Institute is committed to cultivating cutting-edge technologies and projects in Chinese medical device industry, and providing it with multi-faceted technologies, policies, talents, industrialization and markets through direct investment, entrepreneurial services, and scientific and technological achievement transformation services. Integration of services and resources to create an innovative platform for national technological innovation and industrial integration and empowerment. At the same time, it has also become an enabling platform for post-investment enterprises of Guoqian Fund. By creating industrial clusters and industrial ecology, it will provide post-investment management, post-investment services, and post-investment empowerment to post-investment enterprises.
Based on the business philosophy of “achieving the dreams of others”, Guoqian Medical uses market-oriented and specialized equity investment funds to create industrial agglomeration and industrial ecology; it empowers post-investment enterprises by creating industrial agglomeration and industrial ecology. The two platforms complement each other, and strive to build a medical device industry cluster and ecosystem in Suzhou High-tech Zone in 10 years, becoming one of the main promoters of the domestic medical device industry.

Calciscon develops and markets diagnostic devices for the assessment of calcification- and cardiovascular risk to improve disease management of kidney patients worldwide. Our flagship product T50 is the only test capable of accurately predicting the prognosis of a kidney patient. Across 30+ peer-reviewed studies, T50 was demonstrated to accurately predict progression of vascular calcification, cardiovascular events and death. T50 is the only reliable test to individualize the treatment modality of kidney patient to improve prognosis.

Focus-X is a preclinical stage biotech company committed to the discovery and development of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.

Wuxi High-tech zone is focusing on developing biopharmaceutical industry. It is one of the top high-tech zones in China. There are a number of famous biopharmaceutical companies such as AstraZeneca, Wuxi AppTech.

HebeCell was founded in 2016 by industry leading inventors in developing the manufacturing platform of hematopoietic cells from human pluripotent stem cells (PSCs). Their first-in-class proprietary 3D manufacturing platform for human iPS-NK cells is feeder-free, designed specifically for single-use-bioreactor at industrial scale. HebeCell’s platform will accelerate the application of PSCs as a viable source of immune cells in the next generation of immune cell therapies for immune-Oncology, autoimmune and infectious diseases.

Dr. John Lu is the President and CEO of HebeCell. Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which in 2016 was acquired by Astellas, the second-largest pharmaceutical company in Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experience in the field.

Dr. Allen Feng is the Chief Scientific Officer of the HebeCell Corp. Prior to establishing HebeCell, he was the Director of Cell Biology of Semma Therapeutics, which was acquired by Vertex Pharmaceuticals in 2019. Prior to Semma, Allen worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore, and also served as Director and Senior Scientist at Advanced Cell Technology /Ocata Therapeutics.